Daewoong-Medytox botox fight to end without winner
(WorldNews South Korea)

USITC bans Daewoong Nabota`s US entry for 10 years By Nam Hyun-woo Daewoong Pharmaceutical`s Nabota / Courtesy of Daewoong Pharmaceutical The long-drawn-out legal battle between Medytox and Daewoong Pharmaceutical over the origin of their botulinum toxin (BTX) strains is expected to end up hurting both companies, as the U.S. International Trade Commission (USITC) on Tuesday made an initial determination banning the import of Daewoong`s Nabota BTX into the country for 10 years, following Medytox`s accusation. Since Korea`s drug authority decided to suspend the manufacture, sale and use of Medytox`s BTX, Meditoxin, in Korea, industry officials say the four-year battle between the two companies...